Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol

• Published in: Pharmaceutics Vol. 14; no. 1; p. 167
• Main Authors: Lu, Chu-Hsun, Huang, Yu-Feng, Chu, I-Ming
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.01.2022; MDPI
• Subjects: Cellulose; Compliance; Design of experiments; dissolution; Drug dosages; modeling and simulation; Multiple sclerosis; pellets; Permeability; Pharmacokinetics; Respiratory diseases; Scanning electron microscopy; sobrerol; sustained-release; United States > US; Japan; Taiwan; modeling and simulation; IVIVC; multiple sclerosis; pharmacodynamics; dissolution; sustained-release; pellets; pharmacokinetics; sobrerol
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14010167

Sobrerol, an oral mucolytic agent, in a recent study showed promise for treating multiple sclerosis. A human equivalent dose of 486 mg of sobrerol administered thrice daily (i.e., 1459 mg of daily dose) demonstrated the highest therapeutic efficacy for repurposing use, which also points out the poor compliance of administration. In this study, oral sustained-release pellets of sobrerol were successfully developed with evaluated manufacturing conditions and drug release kinetics. For design of the target drug product, we used a modeling and simulation approach to establish a predictive model of oral pharmacokinetic profile, by exploring the characteristics and correlations corresponding to the pharmacokinetics and pharmacodynamics of sobrerol, such as absorption lag time (0.18 h), time-scaling in vitro–in vivo correlation (tin-vitro = 0.494 tin-vivo − 0.0904), gastrointestinal transit time (8 h), minimum effective concentration (1.61 μg/mL), and duration of action (12.8 h). Results showed that the frequency of administration and the daily dose remarkably reduced by 33.3% (i.e., from thrice to twice daily) and 22.8%, respectively, which indicates that this prototype approach can be adopted for rapidly developing a modified-release dosage form of sobrerol, with improvement of compliance of administration and therapeutic efficacy.